Ruxolitinib, targeting JAK-STAT signaling, was commonly used to treat myelofibrosis68 showed increased sensitivity in ccRCC tumors highly expressed STAT1, suggesting that targeting JAK-STAT signaling might possess of double effects, including inhibiting the tumor growth directly and regulation immune response. Here, STAT1 is linked to nonpapillary renal cell carcinoma.